Qing Rao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qing Rao has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Jianxiang Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
34 shared publications Haiyan Xing
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
17 shared publicationsMin Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
17 shared publications- Min Wang
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
17 shared publications Zheng Tian
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
16 shared publicationsKejing Tang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
14 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72395
Transcriptome Analysis Identifies a Myeloid‐Like Signature in Relapsed or Refractory B ‐Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy
Background: Relapsed or refractory B‐cell acute lymphoblastic leukemia (R/R B‐ALL) patients exhibit heterogeneous responses to CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy. However, current studies primarily focus on the CAR‐T cells or the leukemia blasts, and the patient's intrinsic molecular characteristics before treatment remain poorly understood. Methods: Fifteen R/R B‐ALL patients enrolled in a phase II, single‐arm clinical trial (NCT04684147) were stratified at a three‐month landmark into 8 good responders and 7 poor responders. Clinical characteristics, genetic alterations and pre‐treatment bone marrow transcriptomics were compared between groups, and an exploratory gene‐expression score was derived. Results: Differential expression and enrichment analyses identified a myeloid‐like signature and upregulation of myeloid‐related genes in poor responders. Seven myeloid‐related genes were examined in independent patient cohorts, in B‐ALL cell lines and at single‐cell resolution in one patient; three were expressed by the leukemic cells themselves and four predominantly by monocytes and macrophages. A separate, variance‐derived seven‐gene least absolute shrinkage and selection operator (LASSO) score separated response groups in the discovery cohort (apparent area under the curve, AUC 1.00), with bias‐corrected and external estimates of approximately 0.57–0.59 (external cohort AUC 0.592, 95% confidence interval 0.356–0.828). Conclusions: Pre‐treatment transcriptomic profiling revealed a myeloid‐like signature in R/R B‐ALL patients with poor CD19 CAR‐T response, warranting further investigation as a candidate correlate of treatment outcome.
- 19 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72395
Open AccessTranscriptome Analysis Identifies a Myeloid‐Like Signature in Relapsed or Refractory B ‐Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy
Background: Relapsed or refractory B‐cell acute lymphoblastic leukemia (R/R B‐ALL) patients exhibit heterogeneous responses to CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy. However, current studies primarily focus on the CAR‐T cells or the leukemia blasts, and the patient's intrinsic molecular characteristics before treatment remain poorly understood. Methods: Fifteen R/R B‐ALL patients enrolled in a phase II, single‐arm clinical trial (NCT04684147) were stratified at a three‐month landmark into 8 good responders and 7 poor responders. Clinical characteristics, genetic alterations and pre‐treatment bone marrow transcriptomics were compared between groups, and an exploratory gene‐expression score was derived. Results: Differential expression and enrichment analyses identified a myeloid‐like signature and upregulation of myeloid‐related genes in poor responders. Seven myeloid‐related genes were examined in independent patient cohorts, in B‐ALL cell lines and at single‐cell resolution in one patient; three were expressed by the leukemic cells themselves and four predominantly by monocytes and macrophages. A separate, variance‐derived seven‐gene least absolute shrinkage and selection operator (LASSO) score separated response groups in the discovery cohort (apparent area under the curve, AUC 1.00), with bias‐corrected and external estimates of approximately 0.57–0.59 (external cohort AUC 0.592, 95% confidence interval 0.356–0.828). Conclusions: Pre‐treatment transcriptomic profiling revealed a myeloid‐like signature in R/R B‐ALL patients with poor CD19 CAR‐T response, warranting further investigation as a candidate correlate of treatment outcome.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis.Significance:Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis.Significance:Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- Open Access
- 7 July 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (11) , 3156-3174
The critical role of DNA damage‐inducible transcript 4 ( DDIT4 ) in stemness character of leukemia cells and leukemia initiation
Leukemia stem cells (LSCs) are critical for leukemia initiation, and the stemness properties of LSCs are related to disease relapse. Stemness properties, including quiescence, self‐renewal, and chemoresistance, are maintained through an interplay between leukemia cells and the bone marrow (BM) niche. Here, we demonstrated that DNA damage‐inducible transcript 4 (DDIT4) can be induced in a hypoxic BM niche and is required for the quiescence and self‐renewal of AML1‐ETO9a (AE9a)‐transformed leukemia cells in vitro . More importantly, analysis of publicly available transcriptional data from adult acute myeloid leukemia (AML) patients revealed that elevated DDIT4 expression correlates with poor prognosis. Furthermore, DDIT4 knockout markedly suppressed leukemia initiation, quiescence, chemoresistance, and self‐renewal of AE9a‐transformed leukemia cells in vivo . Mechanistically, DDIT4 upregulates the expression of HOXA gene cluster, and re‐expression of HOXA6 in DDIT4 knockout AE9a cells can rescue the impaired leukemia initiation. Our findings demonstrate the critical role of DDIT4 in the stemness of AE9a leukemia cells and elucidate its underlying mechanism, suggesting that targeting DDIT4 may represent a promising therapeutic strategy for eliminating LSCs in AML1‐ETO leukemia.
- 7 July 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (11) , 3156-3174
Open AccessThe critical role of DNA damage‐inducible transcript 4 ( DDIT4 ) in stemness character of leukemia cells and leukemia initiation
Leukemia stem cells (LSCs) are critical for leukemia initiation, and the stemness properties of LSCs are related to disease relapse. Stemness properties, including quiescence, self‐renewal, and chemoresistance, are maintained through an interplay between leukemia cells and the bone marrow (BM) niche. Here, we demonstrated that DNA damage‐inducible transcript 4 (DDIT4) can be induced in a hypoxic BM niche and is required for the quiescence and self‐renewal of AML1‐ETO9a (AE9a)‐transformed leukemia cells in vitro . More importantly, analysis of publicly available transcriptional data from adult acute myeloid leukemia (AML) patients revealed that elevated DDIT4 expression correlates with poor prognosis. Furthermore, DDIT4 knockout markedly suppressed leukemia initiation, quiescence, chemoresistance, and self‐renewal of AE9a‐transformed leukemia cells in vivo . Mechanistically, DDIT4 upregulates the expression of HOXA gene cluster, and re‐expression of HOXA6 in DDIT4 knockout AE9a cells can rescue the impaired leukemia initiation. Our findings demonstrate the critical role of DDIT4 in the stemness of AE9a leukemia cells and elucidate its underlying mechanism, suggesting that targeting DDIT4 may represent a promising therapeutic strategy for eliminating LSCs in AML1‐ETO leukemia.
- 15 April 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (5) , 1275
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway
- 15 April 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (5) , 1275
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway
- 13 January 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 228, 379-391
U2AF1 mutation causes an oxidative stress and DNA repair defect in hematopoietic and leukemic cells
- 13 January 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 228, 379-391
U2AF1 mutation causes an oxidative stress and DNA repair defect in hematopoietic and leukemic cells
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends